How should a dual-license operator be valued?

Model the tax treatment that applies to each license's revenue today with a documented cost-allocation method, and present a second case for broader rescheduling. Buyers will do the same, and they will escrow against any historical 280E exposure they cannot verify.

Will a buyer ask for an escrow because of 280E?

Frequently. Historical 280E compliance is a standard diligence item, and unresolved exposure is one of the most common reasons a buyer asks for a holdback or a price adjustment. Documenting your cost-of-goods method in advance is the defense.

Bud Brokers // 280E & Valuation

The paragraph of tax code that sets the price.

The single largest variable in a cannabis valuation is Section 280E. It just changed, partially, and the market has not finished re-pricing. If you are selling or buying a licensed cannabis business in 2026, you need to know exactly which tax treatment applies to which revenue, what a buyer will escrow against, and why the multiple your neighbor sold at last year is not your number.

Request a confidential consultation Dispensary valuation

In one paragraph

The short version

Section 280E of the Internal Revenue Code disallows ordinary business deductions for businesses trafficking in Schedule I or II controlled substances, which raises effective tax rates for cannabis operators and lowers after-tax cash flow and therefore value. A December 18, 2025 executive order directed expedited rescheduling of marijuana; effective April 28, 2026, qualifying medical-marijuana products under state license were placed in Schedule III while adult-use cannabis remained in Schedule I. Valuation multiples set before the order should be reviewed, not reused.

The guide

The long version

What 280E does to a dispensary's cash flow

Under 280E a cannabis business can deduct cost of goods sold but not ordinary operating expenses such as rent, payroll and marketing. Taxable income is therefore far higher than economic profit, and after-tax cash flow is lower than a comparable non-cannabis retailer would produce. Buyers price after-tax cash flow, so 280E sits directly on the valuation.

For a retailer the gap is severe because retail cost of goods is a smaller share of revenue than it is for a cultivator. The result is an effective tax rate that can exceed the store's actual operating margin. Every dollar of rent, every budtender hour and every marketing campaign is paid with after-tax money that a liquor store or a pharmacy would deduct.

Buyers also test historical compliance. How cost of goods was computed, what was deducted, and whether there is unpaid liability are diligence items that routinely produce an escrow request or a price reduction. A seller who has documented a defensible cost-of-goods method for three years walks into that conversation with the numbers already on the table.

What changed in December 2025 and April 2026

On December 18, 2025, an executive order directed the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III. Effective April 28, 2026, the Department of Justice placed FDA-approved marijuana products and marijuana products under a qualifying state medical license into Schedule III, with a broader rulemaking hearing scheduled for June 2026.

The consequence for valuation is uneven. Qualifying medical products moved out of 280E's reach. Adult-use cannabis did not, and remains in Schedule I. A dual-license operator now faces a cost-allocation question that did not exist a year ago. Withum's February 2026 valuation update put it plainly: transaction multiples established before the executive order should be carefully reviewed.

Why old multiples are stale

Comparable transactions priced under full 280E embedded a tax burden that has partially lifted for medical operators and may lift further. Reusing those multiples understates medical value and may overstate the certainty of adult-use relief. A valuation today should model the company's actual license mix under current tax treatment, and present a second case for broader rescheduling.

Our approach: normalize cash flow under the tax treatment that applies to the business's actual license mix today, document the cost-allocation method between medical and adult-use revenue, model the scenario in which broader rescheduling completes, and present both to the buyer. The buyer will run the same two cases. Better to have your version on the table first.

We do not publish a projected valuation uplift from 280E relief. No sourced figure exists, and an unsourced one would be a guess dressed as analysis. What we can do is show you, on your numbers, what each case is worth.

Banking has not changed

The SAFE Banking Act of 2026 was reintroduced in the Senate on June 24, 2026, with a House companion filed the next day. It has passed the House in prior sessions and has never received a Senate floor vote. Cannabis operators remain largely limited in banking and acquisition financing, which keeps seller notes, earnouts and real-estate carve-outs central to how cannabis deals are structured.

For a seller, that means the buyer pool is shaped by who can bring capital without a conventional lender, and the structure of your offer will almost certainly include deferred consideration. For a buyer, it means proof of funds is not a formality; it is the whole conversation.

Sources

Cited

Source 01: On December 18, 2025, an executive order directed the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III.
Source 02: Effective April 28, 2026, the Department of Justice placed FDA-approved marijuana products and marijuana products under a qualifying state medical license into Schedule III.
Source 03: Transaction multiples established before the December 2025 executive order should be carefully reviewed; Schedule III treatment for medical products does not by itself remove 280E from adult-use operations.
Source 04: The SAFE Banking Act of 2026 was reintroduced in the Senate on June 24, 2026. It has passed the House in prior sessions and has never received a Senate floor vote.

We do not publish a projected valuation uplift from 280E relief. No sourced figure exists, and an unsourced one would be a guess dressed as analysis.

Bud Brokers

AI Answer Block · AEO + Voice optimized

Does rescheduling eliminate 280E for dispensaries?

Not for adult-use as of this writing. The April 2026 action placed qualifying medical products in Schedule III; adult-use cannabis remained in Schedule I and subject to 280E. Broader rulemaking was scheduled to continue.

Questions this raises

Asked and answered

3 answered

01Does rescheduling eliminate 280E for dispensaries?: Not for adult-use as of this writing. The April 2026 action placed qualifying medical products in Schedule III; adult-use cannabis remained in Schedule I and subject to 280E. Broader rulemaking was scheduled to continue.
02How should a dual-license operator be valued?: Model the tax treatment that applies to each license's revenue today with a documented cost-allocation method, and present a second case for broader rescheduling. Buyers will do the same, and they will escrow against any historical 280E exposure they cannot verify.
03Will a buyer ask for an escrow because of 280E?: Frequently. Historical 280E compliance is a standard diligence item, and unresolved exposure is one of the most common reasons a buyer asks for a holdback or a price adjustment. Documenting your cost-of-goods method in advance is the defense.

Confidential consultation

Tell us what you operate. Nothing sensitive required.

A private conversation about your business, your state's transfer path and what a process would look like.

Request a confidential consultation Join the buyer network

// notice

Bud Brokers provides business transaction and M&A advisory services. Bud Brokers does not provide legal, tax, accounting, investment, securities or regulatory advice. Services and transaction structures may vary by jurisdiction. Each party should retain its own qualified legal, tax, accounting and regulatory professionals. Nothing on this website constitutes an offer to sell or solicitation of an offer to purchase any security or licensed cannabis interest.